Trusence Every claim has a source
Last updated 17 November 2026 Search Türkçe
Funding

Isomorphic Labs raises $5 billion to move AI-designed drugs toward clinical trials

The funding will push the company's preclinical drug candidates into human testing and widen its work into new therapeutic areas.

Isomorphic Labs, the AI drug-discovery company spun out of Google DeepMind in 2021, has closed a $5 billion Series C round to move its drug candidates into clinical trials. Greenoaks and Sequoia Capital co-led the round, with Andreessen Horowitz joining as a new investor and existing backers including GV, Capital G, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund also participating. The company says its platform has produced encouraging preclinical results in oncology and immunology and has partnerships with Eli Lilly, Novartis and Johnson & Johnson. The raise follows a $2.1 billion Series B in May and will fund further work on its drug-design engine and expansion into additional therapeutic areas. It is the first fundraise since Demis Hassabis stepped back from DeepMind to focus on drug discovery, and the company did not disclose its valuation, though Bloomberg had reported a target of $50 billion.

Why it matters

The round signals that investors are willing to back AI-led drug discovery at a scale usually reserved for late-stage biotech, and that the sector is moving from computational promise toward human trials. For patients and pharmaceutical partners, the practical question is whether the preclinical results in oncology and immunology hold up in clinical testing. Until they do, the valuation and the size of the raise say more about expectations than about proven medicines.

Sources · 1